News & Media

July 11, 2022
Optimizing Process Development Early – A critical factor in successful viral vector scale up and large scale manufacture
September 23, 2021
The analytical requirements for viral vectors used to deliver gene therapies are complex and constantly evolving. The keys to success,...
September 16, 2021
The number of gene therapy candidates in development is growing rapidly, with many advancing toward late-stage trials. The majority of...
Media Release
August 25, 2021
TetraScience, the R&D Data Cloud company, announced today that Andelyn Biosciences, Inc. has selected the Tetra Data Platform (TDP) to build a cloud-native development and manufacturing service for its customers.
August 23, 2021
Abstract: Andelyn Biosciences, a full-spectrum gene therapy CDMO organization that supports clients from preclinical studies through phase III trials, originally...
June 20, 2021
Adeno-associated viruses (AAV) are small viruses that can infect humans and other primate species. The particularity about AAV is that...
Media Release
March 18, 2021
COLUMBUS, Ohio – Andelyn Biosciences, Inc, a contract development and manufacturing organization (CDMO) and an affiliate company of Nationwide Children’s Hospital, has...
February 15, 2021
“What’s in a name?” the saying goes. In this case, much more than meets the eye. Andelyn Biosciences is much...
Media Release
November 25, 2020
COLUMBUS, Ohio – Andelyn Biosciences, an affiliate company of Nationwide Children’s Hospital that manufactures gene therapy products for the biotechnology and pharmaceutical...
November 15, 2020
Viral vectors are an essential part of gene therapy treatments. They are essential for delivering corrected genetic information to faulty...
September 15, 2020
Gene therapy has revolutionized medicine since the early 1990s and is one of the most promising fields in medicine. In...